On Friday, CRISPR Therapeutics AG (NASDAQ: CRSP) opened lower -6.98% from the last session, before settling in for the closing price of $72.82. Price fluctuations for CRSP have ranged from $30.04 to $72.95 over the past 52 weeks.
Company’s average yearly earnings per share was noted -45.12% at the time writing. With a float of $86.11 million, this company’s outstanding shares have now reached $88.38 million.
CRISPR Therapeutics AG (CRSP) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of CRISPR Therapeutics AG is 5.33%, while institutional ownership is 77.15%. The most recent insider transaction that took place on Aug 18 ’25, was worth 760,660. In this transaction Chief Executive Officer of this company sold 13,081 shares at a rate of $58.15, taking the stock ownership to the 207,004 shares. Before that another transaction happened on Aug 06 ’25, when Company’s Director bought 20,000 for $57.03, making the entire transaction worth $1,140,600. This insider now owns 22,000 shares in total.
CRISPR Therapeutics AG (CRSP) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -1.01 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -1.4) by 0.39. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -45.12% per share during the next fiscal year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Check out the current performance indicators for CRISPR Therapeutics AG (CRSP). In the past quarter, the stock posted a quick ratio of 16.61. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 161.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.42, a number that is poised to hit -1.26 in the next quarter and is forecasted to reach -4.16 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
Compared to the last year’s volume of 2.56 million, its volume of 2.92 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 84.22%.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 84.11%, which indicates a significant increase from 64.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 3.65 in the past 14 days, which was higher than the 2.79 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $57.94, while its 200-day Moving Average is $46.38. Nevertheless, the first resistance level for the watch stands at $71.89 in the near term. At $76.04, the stock is likely to face the second major resistance level. The third major resistance level sits at $78.13. If the price goes on to break the first support level at $65.65, it is likely to go to the next support level at $63.56. Should the price break the second support level, the third support level stands at $59.41.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
There are currently 90,950K shares outstanding in the company with a market cap of 6.16 billion. Presently, the company’s annual sales total 37,310 K according to its annual income of -366,250 K. Last quarter, the company’s sales amounted to 890 K and its income totaled -208,550 K.
